It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Induction of DNA double-strand breaks (DSBs) in ribosomal DNA (rDNA) repeats is associated with ATM-dependent repression of ribosomal RNA synthesis and large-scale reorganization of nucleolar architecture, but the signaling events that regulate these responses are largely elusive. Here we show that the nucleolar response to rDNA breaks is dependent on both ATM and ATR activity. We further demonstrate that ATM- and NBS1-dependent recruitment of TOPBP1 in the nucleoli is required for inhibition of ribosomal RNA synthesis and nucleolar segregation in response to rDNA breaks. Mechanistically, TOPBP1 recruitment is mediated by phosphorylation-dependent interactions between three of its BRCT domains and conserved phosphorylated Ser/Thr residues at the C-terminus of the nucleolar phosphoprotein Treacle. Our data thus reveal an important cooperation between TOPBP1 and Treacle in the signaling cascade that triggers transcriptional inhibition and nucleolar segregation in response to rDNA breaks.
DNA double-strand breaks in ribosomal DNA repeats is associated with repression of ribosomal RNA synthesis. Here the authors reveal a cooperation between TOPBP1 and Treacle in the signaling cascade that triggers transcriptional inhibition and nucleolar segregation in response to rDNA breaks.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Zurich, Department of Gynecology, Schlieren, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
2 University of Oxford, John Radcliffe Hospital, Department of Oncology, Medical Research Council Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.7400.3) ; University of Oxford, Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of Copenhagen, Faculty of Health and Medical Sciences, The Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
4 University of Oxford, John Radcliffe Hospital, Department of Oncology, Medical Research Council Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.5254.6) ; University of Oxford, Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)